Document Detail


The role of the new beta-blockers in treating cardiovascular disease.
MedLine Citation:
PMID:  16373195     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The beta-adrenergic receptor blockers play an important role in the management of cardiovascular disease, including hypertension and chronic heart failure. However, concerns regarding safety and tolerability with currently available agents can limit their use. The beta-blockers vary with regard to several pharmacologic properties, including beta1/beta2 selectivity, intrinsic sympathomimetic activity, and, with the newest beta-blockers, vasodilation. These pharmacologic differences may result in clinically important differences in tolerability and hemodynamic properties. Nebivolol is a novel beta-blocker with both a greater degree of selectivity for beta1-adrenergic receptors than other agents in this class and an ability to stimulate endothelial nitric oxide production, leading to vasodilation and other potential clinical effects. Published randomized, controlled, multicenter studies with nebivolol have shown that once-daily treatment significantly reduces systolic and diastolic blood pressure in patients with mild-to-moderate hypertension, compared with placebo, in a dose-dependent manner, and is well tolerated, with an adverse event profile similar to that of placebo. When compared with other beta-blockers as well as with other antihypertensive classes of agents in head-to-head trials, nebivolol demonstrated similar antihypertensive efficacy and a lower incidence of adverse events. Nebivolol has also been shown to significantly reduce morbidity and mortality in a large population of elderly patients with chronic heart failure, independent of left ventricular ejection fraction. Nebivolol is currently available in Europe for the management of hypertension and is expected to be available soon in the United States.
Authors:
Michael A Weber
Related Documents :
14504635 - Value of propranolol-induced heart rate and blood pressure changes in predicting result...
2034475 - Do beta-adrenergic blockade and sleep state affect cardiorespiratory control in neonata...
24566895 - Potential application of in vivo imaging of impaired lymphatic duct to evaluate the sev...
23955535 - Dressings and topical agents for preventing pressure ulcers.
22689545 - Unusual cause of acquired brain injury.
11812705 - The effect of nitrous oxide on jugular bulb oxygen saturation during remifentanil plus ...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  American journal of hypertension     Volume:  18     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-12-23     Completed Date:  2006-02-03     Revised Date:  2009-02-24    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  169S-176S     Citation Subset:  IM    
Affiliation:
Department of Medicine, State University of New York, Brooklyn, New York, USA. minskyja@cs.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adrenergic beta-Antagonists / therapeutic use*
Adult
Aged
Antihypertensive Agents / therapeutic use*
Atenolol / therapeutic use
Benzopyrans / adverse effects,  therapeutic use*
Cardiovascular Diseases / drug therapy*
Clinical Trials as Topic
Enalapril / therapeutic use
Ethanolamines / adverse effects,  therapeutic use*
Female
Heart Failure / drug therapy
Hemodynamics / drug effects
Humans
Hypertension / drug therapy
Labetalol / therapeutic use
Losartan / therapeutic use
Male
Metoprolol / adverse effects,  therapeutic use
Middle Aged
Nifedipine / therapeutic use
Receptors, Adrenergic, beta-1 / drug effects
Receptors, Adrenergic, beta-2 / drug effects
Sympathomimetics / therapeutic use
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Benzopyrans; 0/Ethanolamines; 0/Receptors, Adrenergic, beta-1; 0/Receptors, Adrenergic, beta-2; 0/Sympathomimetics; 114798-26-4/Losartan; 21829-25-4/Nifedipine; 29122-68-7/Atenolol; 36894-69-6/Labetalol; 37350-58-6/Metoprolol; 75847-73-3/Enalapril; 99200-09-6/nebivolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of beta-blockers as a cornerstone of cardiovascular therapy.
Next Document:  Exploring vascular benefits of endothelium-derived nitric oxide.